Fidelity Advisor Biotechnology C FBTCX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 25.79  /  +0.27 %
  • Total Assets 1.9 Bil
  • Adj. Expense Ratio
    1.760%
  • Expense Ratio 1.730%
  • Distribution Fee Level Low
  • Share Class Type Level Load
  • Category Health
  • Investment Style Mid Growth
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 0.00
  • Turnover 73%

USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 10:13 PM GMT+0

Morningstar’s Analysis FBTCX

Will FBTCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

An incline in its Process Pillar rating is the primary driver of Fidelity Advisor Biotechnology C's upgrade to a Morningstar Medalist Rating of Bronze from Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 58.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

18.21 329.4 Mil
Healthcare

Amgen Inc

9.43 170.7 Mil
Healthcare

Regeneron Pharmaceuticals Inc

7.01 126.8 Mil
Healthcare

Vertex Pharmaceuticals Inc

4.72 85.5 Mil
Healthcare

Alnylam Pharmaceuticals Inc

4.53 82.0 Mil
Healthcare

argenx SE ADR

3.76 68.1 Mil
Healthcare

Ascendis Pharma A/S ADR

3.50 63.4 Mil
Healthcare

Vaxcyte Inc Ordinary Shares

2.61 47.2 Mil
Healthcare

Cytokinetics Inc

2.60 47.0 Mil
Healthcare

Viking Therapeutics Inc

2.26 40.9 Mil
Healthcare

Sponsor Center